N.D. Ga. (2006)
Fitzpatrick, Cella, on behalf of clients UCB and UCB Pharma, obtained a favorable Markman decision against Mylan, Dr. Reddy’s, Sandoz, Cobalt and Ivax/Teva in a Hatch-Waxman patent infringement action involving UCB’s anti-epilepsy drug, Keppra® . After conducting a Markman hearing, Judge Duffey (Northern District of Georgia), rendered a 19 page decision accepting the claim construction proposed by UCB and rejecting the constructions proposed by the generic defendants.
Scott K. Reed argued for UCB at the hearing. Robert L. Baechtold, Bruce C. Haas, Steven C. Kline, Ha Kung Wong, James M. Fukuyama, Haiyan Chen and Jason Johnson also appeared for UCB at the hearing.